Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DP-R208 vs Monotherapies in Hypertension and Primary Hypercholesterolemia
NCT02770261Phase 3Completed
- Sponsor
- Alvogen
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of candesartan cilexetil, rosuvastatin in hypertension (HTN), hypercholesterolemia, sponsored by Alvogen. Started Dec 2015; status: completed.
02
Drugs
candesartan cilexetilrosuvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02770261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770261.